HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shanghai Bio-Heart Biological Technology (2185.HK) - The Bubble Will Eventually Burst

China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes

China Healthcare Weekly (May.12) - Three Globalization Strategies, GLP-1/Weight Loss Drug, Bio-Heart

Pre-IPO Shanghai Hanyu Medical Technology - Insights on the Industry and the Products

Pre-IPO Shanghai Bio-Heart Biological Technology - Here Are the Strength and Concerns

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Shanghai Bio-Heart Biological Technology / Equity Capital Markets

Shanghai Bio-Heart Biological Technology (2185 HK)

<ul>
<li>The possibility of centralized procurement on BRS should be aware of.</li>
<li>It's not sure if Iberis 2<sup>nd </sup>would be recognized and accepted by the market as expected.</li>
<li>Together with other concerns, we are conservative about the outlook of Bio-heart.</li>
</ul>


The possibility of centralized procurement on BRS should be aware of.
It's not sure if Iberis 2nd would be recognized and accepted by the market as expected.
Together with other concerns, we are conservative about the outlook of Bio-heart.


Pre-IPO Shanghai Bio-Heart Biological Technology - Conservative About the Outlook